• Effects of Qixuekang oral liquid in leukopenia during chemotherapy and radiotherapy in patients with malignant tumors: A randomized, double-blind, placebo-controlled, multicenter study

    ObjectiveTo assess the efficacy and safety of Qixuekang oral liquid in the treatment of leukopenia during chemotherapy and radiotherapy.MethodsThis randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted between July 2018 and May 2021. A total of 234 patients with malignant tumors were enrolled from 12 medical centers. They were randomly assigned to receive either Qixuekang oral liquid or placebo in addition to standard chemotherapy and radiotherapy, with a treatment duration ≤42 days. The primary outcome was defined as the change in peripheral white blood cell (WBC) count, determined by routine laboratory hematology tests, from baseline (D-7 to D0) to Day 42 (±2 days) of dosing (D42).ResultsIn the full analysis set comprising 227 patients (113 and 114 in the experimental and control groups, respectively), a significant reduction in WBC count was observed after treatment (P < .001). The experimental group exhibited a smaller reduction in WBC count than did the control group (P = .038). In the per-protocol set (n = 188), a trend favoring the experimental group was evident, although not statistically significant (P = .091). No significant differences were observed in the vital signs, laboratory results, or adverse events between the two groups (P > .05).ConclusionQixuekang oral liquid may exert a therapeutic effect in mitigating leukopenia induced by chemotherapy and radiotherapy, while exhibiting favorable safety profiles.

    Yafang Cai, Peng Xue, Xinyu Hu, Huijie Wang, Liping Liu, Yi Li, Jun Xiao, Changgang Sun, Yufeng Wang, Shijie Zhu

    4 May 2026
  • Current Issue:

    Vol.13  Issue 2, 2026

Recommend Articles MORE

Ginger oil-loaded transdermal adhesive patch treats post-traumatic stress disorder

ObjectiveTo find a viable alternative to reduce the number of doses required for the patients with post-traumatic stress disorder (PTSD), and to improve efficacy and patient compliance.MethodsIn this study, we used ginger oil, a phytochemical with potential therapeutic properties, to prepare ginger oil patches. High-performance liquid chromatography (HPLC) was used to quantify the main active component of ginger oil, 6-gingerol. Transdermal absorption experiments were conducted to optimize the various pressure-sensitive adhesives and permeation enhancers, including their type and concentration. Subsequently, the ginger oil patches were optimized and subjected to content determination and property evaluations. A PTSD mouse model was established using the foot-shock method. The therapeutic effect of ginger oil patches on PTSD was assessed through pathological sections, behavioral tests, and the evaluation of biomarkers such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), brain-derived neurotrophic factor (BDNF), and melatonin (MT).ResultsThe results demonstrated that ginger oil patches exerted therapeutic effects against PTSD by inhibiting inflammatory responses and modulating MT and BDNF levels. Pharmacokinetic experiments revealed that ginger oil patches maintained a stable blood drug concentration for at least one day, addressing the rapid metabolism drawback of 6-gingerol and enhancing its therapeutic efficacy.ConclusionsGinger oil can be prepared as a transdermal drug patch that meets these requirements, and the bioavailability of the prepared patch is better than that of oral administration. It can improve PTSD with good patient compliance and ease of administration. Therefore, it is a promising therapeutic formulation for the treatment of PTSD.

Xingshuang Song, Yizhi Zhang, Ziyan Tang, Jing Dai, Yanping Wu, Guiyu Huang, Hong Niu, Yaxin Wang, Xu Jin, Lina Du

article 3 Aug 2024
0